Glufosfamide
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Glufosfamide
- DrugBank Accession Number
- DB06177
- Background
Not Available
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 383.16
Monoisotopic: 382.0463434 - Chemical Formula
- C10H21Cl2N2O7P
- Synonyms
- Glufosfamide
- External IDs
- D 19575
- D-19575
Pharmacology
- Indication
Investigated for use/treatment in pancreatic cancer, solid tumors, breast cancer, colorectal cancer, brain cancer, lung cancer, ovarian cancer, and sarcoma.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as hexoses. These are monosaccharides in which the sugar unit is a is a six-carbon containing moeity.
- Kingdom
- Organic compounds
- Super Class
- Organic oxygen compounds
- Class
- Organooxygen compounds
- Sub Class
- Carbohydrates and carbohydrate conjugates
- Direct Parent
- Hexoses
- Alternative Parents
- Phosphoric monoester diamides / Phosphate esters / Oxanes / Secondary alcohols / Polyols / Oxacyclic compounds / Primary alcohols / Organopnictogen compounds / Organonitrogen compounds / Organochlorides show 3 more
- Substituents
- Alcohol / Aliphatic heteromonocyclic compound / Alkyl chloride / Alkyl halide / Hexose monosaccharide / Hydrocarbon derivative / Organic nitrogen compound / Organic oxide / Organic phosphoric acid amide / Organic phosphoric acid derivative show 12 more
- Molecular Framework
- Aliphatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 1W5N8SZD9A
- CAS number
- 132682-98-5
- InChI Key
- PSVUJBVBCOISSP-SPFKKGSWSA-N
- InChI
- InChI=1S/C10H21Cl2N2O7P/c11-1-3-13-22(19,14-4-2-12)21-10-9(18)8(17)7(16)6(5-15)20-10/h6-10,15-18H,1-5H2,(H2,13,14,19)/t6-,7-,8+,9-,10+/m1/s1
- IUPAC Name
- (2S,3R,4S,5S,6R)-2-({bis[(2-chloroethyl)amino]phosphoryl}oxy)-6-(hydroxymethyl)oxane-3,4,5-triol
- SMILES
- OC[C@H]1O[C@@H](OP(=O)(NCCCl)NCCCl)[C@H](O)[C@@H](O)[C@@H]1O
References
- General References
- Veyhl M, Wagner K, Volk C, Gorboulev V, Baumgarten K, Weber WM, Schaper M, Bertram B, Wiessler M, Koepsell H: Transport of the new chemotherapeutic agent beta-D-glucosylisophosphoramide mustard (D-19575) into tumor cells is mediated by the Na+-D-glucose cotransporter SAAT1. Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):2914-9. [Article]
- External Links
- ChemSpider
- 110215
- ChEMBL
- CHEMBL2107143
- ZINC
- ZINC000003918137
- Wikipedia
- Glufosfamide
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data3 Completed Treatment Pancreatic Cancer 1 somestatus stop reason just information to hide 3 Recruiting Treatment Pancreatic Adenocarcinoma Metastatic 1 somestatus stop reason just information to hide 2 Completed Treatment Brain and Central Nervous System Tumors 1 somestatus stop reason just information to hide 2 Completed Treatment Lung Cancer 1 somestatus stop reason just information to hide 2 Completed Treatment Pancreatic Cancer 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 9.05 mg/mL ALOGPS logP -1.4 ALOGPS logP -2.4 Chemaxon logS -1.6 ALOGPS pKa (Strongest Acidic) 12.17 Chemaxon pKa (Strongest Basic) -0.94 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 7 Chemaxon Hydrogen Donor Count 6 Chemaxon Polar Surface Area 140.51 Å2 Chemaxon Rotatable Bond Count 9 Chemaxon Refractivity 78.35 m3·mol-1 Chemaxon Polarizability 34.33 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-0600-9826000000-6012e94000dc59cfa740 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-001i-0119000000-06ed2df653a3780cb0a5 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-001i-0009000000-a90dedb8b95fc654c4fc Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-00yi-0922000000-69d7379d0c15114d2f73 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0a4l-2900000000-e0238a185140a16a2f8d Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-08mi-6890000000-52ab8ccfb3f3407674dc Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-000f-0910000000-9c9b1d431e39bfa58837 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 175.23528 predictedDeepCCS 1.0 (2019) [M+H]+ 177.59328 predictedDeepCCS 1.0 (2019) [M+Na]+ 185.44235 predictedDeepCCS 1.0 (2019)
Drug created at March 19, 2008 16:15 / Updated at February 21, 2021 18:52